Free Trial
NASDAQ:BNTC

Benitec Biopharma 5/13/2024 Earnings Report

Benitec Biopharma logo
$13.95 -0.48 (-3.33%)
Closing price 05/6/2025 03:59 PM Eastern
Extended Trading
$14.61 +0.66 (+4.73%)
As of 06:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Benitec Biopharma EPS Results

Actual EPS
-$1.64
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Benitec Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Benitec Biopharma Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Benitec Biopharma's next earnings date is estimated for Monday, May 12, 2025, based on past reporting schedules.

Conference Call Resources

Benitec Biopharma Earnings Headlines

Benitec Biopharma price target raised to $20 from $18 at Citizens JMP
Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...
See More Benitec Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Benitec Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Benitec Biopharma and other key companies, straight to your email.

About Benitec Biopharma

Benitec Biopharma (NASDAQ:BNTC), a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

View Benitec Biopharma Profile

More Earnings Resources from MarketBeat